Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m2 for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HN009 is temporarily closed to accrual to the P16-Positive OPC/CUP Cohort, effective October 7, 2024 at 5pm ET.
